ART Terumo 250x150

Promising pre-clinical data on the next generation drug eluting bioresorbable scaffold

Paris, France, May 21 2015 — Terumo and Arterial Remodeling Technologies (ART) announce that, on May 20, 2015, Dr Renu Virmani, internationally renowned cardiovascular pathologist at CVPath Institute, USA, presented promising pre-clinical data on Terumo’s next generation drug eluting bioresorbable scaffold for the treatment of coronary artery disease. “We are particularly satisfied with the well[…]

CE 1

ART Announces CE Mark Clearance for its Pure Bioresorbable Scaffold

Paris, May 18, 2015 – Privately-held company Arterial Remodeling Technologies (“ART”) today announces CE Mark clearance for its next generation drug free, pure bioresorbable scaffold used to treat coronary artery disease. The CE Mark was achieved following the completion of extensive pre- clinical research, including up to three-years of follow-up, and supportive clinical results from[…]

ART Terumo 250x150

ART signs structured buyout agreement with Terumo, validating ART’s scaffold

PARIS, March 27, 2014 – Privately held Arterial Remodeling Technologies (‘ART’) announced today that it has signed a structured buyout agreement with Terumo Corporation. Under the agreement, ART and Terumo Corporation will collaborate in the development of a drug eluting bioresorbable scaffold or stent, intended for use in the treatment of coronary artery disease. ART[…]

Clinique Pasteur 2

ART reports first human use of its next-generation bioresorbable stent

PARIS, July 16, 2012—Arterial Remodeling Technologies (“ART”) reported today that the Company has achieved a medical milestone with its “ARTDIVA” (Arterial Remodeling Transient DIsmantling Vascular Angioplasty) clinical trial: the successful First-in-Human implantation of its novel biodegradable stent into an 61-year-old male who was suffering from a blocked coronary artery and needed a percutaneous coronary intervention[…]

AFSSAPS

ART receives regulatory approval to begin First‐In‐Man “ARTDIVA” clinical trial

PARIS, May 15, 2012—Arterial Remodeling Technologies (“ART”) reported today that it has received regulatory approval in Europe to begin its First‐In‐Man “ARTDIVA” (Arterial Remodeling Transient DIsmantling Vascular Angioplasty) clinical trial next month at five medical centers. ART’s in vivo data strongly suggest that its next‐generation bioresorbable stent is designed to promote positive arterial remodeling.  […]

ART 250x150

ART reports $2.9 million cash infusion to prepare its First-in-Human study

PARIS, April 4, 2012—Arterial Remodeling Technologies (“ART”) reported today that in vivo data strongly suggest that its next-generation bioresorbable stent promotes positive arterial remodeling in a post-angioplasty porcine model at six months follow-up. In addition, acute safety data are promising: there have been more than 300 MACE-free consecutive implantations of its bioresorbable stent in its[…]

Enlargement

ART reports that its bioresorbable stent promotes vessel lumen enlargement

PARIS, Nov. 2, 2011—Arterial Remodeling Technologies (“ART”) reported today that in vivo data strongly suggest that its second-generation bioresorbable stent promotes positive arterial remodeling in a post-angioplasty porcine model at three months follow- up. In addition, acute safety data are excellent: there have been more than 250 MACE- free consecutive implantations of its bioresorbable stent[…]

Stent

ART to disclose for the first time the novel design for its disruptive bioresorbable stent

PARIS, May 17, 2011—Arterial Remodeling Technologies (“ART”) announced today that details of the state-of-the-art design of its potentially disruptive polymer-based bioresorbable stent platform will be revealed, for the first time, at EuroPCR 2011 from the podium tomorrow (Wednesday, May 18). The disclosure will be presented by Antoine LaFont, M.D., Ph.D., Professor of Medicine, Head Interventional[…]

ICI

ART discloses new data for its breakthrough bioresorbable stent at ICI

PARIS, Dec. 7, 2010—Arterial Remodeling Technologies (“ART”) disclosed today new data related to its bioresorbable stent platform—additional data that further validates the Company’s innovative approach to simultaneously balance biocompatibility, biomechanics and bioresorption within a bioresorbable PLA (polylactic acid) stent. The new data show that the ART stent scaffold can be overinflated by more than 25%[…]

ART 250x150

ART raises $8.5 million in new venture financing round from existing investors

PARIS, Sept. 21, 2010—Arterial Remodeling Technologies (“ART”) announced today that it has closed on a new venture financing round of $8.5 million from existing investors Matignon Technologies and Amundi Private Equity Funds, along with new investor InnoBio Fund managed by CDC Entreprises. Total investment in the Company is now $17 million.   ART-News 100921